Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome

Pierre QuartierUnit&eacute; d&#39;Immunologie-H&eacute;matologie et Rhumatologie p&eacute;diatriques, H&ocirc;pital Necker-Enfants Malades, Assistance Publique-H&ocirc;pitaux de Paris, Paris, FranceAbstract: Cryopyrin-associated periodic syndrome (CAPS...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Pierre Quartier
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/446ea80268374ac1b79e916b181dfcf9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:446ea80268374ac1b79e916b181dfcf9
record_format	dspace
spelling	oai:doaj.org-article:446ea80268374ac1b79e916b181dfcf92021-12-02T11:18:04ZInterleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome1179-156Xhttps://doaj.org/article/446ea80268374ac1b79e916b181dfcf92011-01-01T00:00:00Zhttp://www.dovepress.com/interleukin-1-antagonists-in-the-treatment-of-autoinflammatory-syndrom-a6083https://doaj.org/toc/1179-156XPierre QuartierUnit&eacute; d&#39;Immunologie-H&eacute;matologie et Rhumatologie p&eacute;diatriques, H&ocirc;pital Necker-Enfants Malades, Assistance Publique-H&ocirc;pitaux de Paris, Paris, FranceAbstract: Cryopyrin-associated periodic syndrome (CAPS) include a group of rare autoinflammatory disorders, the spectrum of which ranges from the mildest form, ie, familial cold autoinflammatory syndrome to more severe phenotypes, ie, Muckle-Wells syndrome, and chronic infantile neurological cutaneous and articular syndrome, also known as neonatal-onset multisystem inflammatory disease. Three interleukin (IL)-1 antagonists have been tested in adults and children with CAPS, ie, anakinra, a recombinant homolog of the human IL-1 receptor antagonist; rilonacept, a fusion protein comprising the extracellular domains of IL-1 receptor I and the IL-1 adaptor protein, IL-1RAcP, attached to a human immunoglobulin G molecule; and canakinumab, the anti-IL-1&beta; monoclonal antibody. Following rapid clinical development, rilonacept and canakinumab were approved by both the US Food and Drug Administration and the European Medicines Agency for use in adults and children. This review describes how the study of CAPS has helped us to understand better the way the innate immune system works, the pathogenesis of autoinflammatory syndromes, and the key role of IL-1. It also reviews the effects of IL-1 blockade in CAPS and other disorders, in particular systemic juvenile idiopathic arthritis, adult-onset Still&#39;s disease, and gout. Finally, this review covers some issues addressed by very recent and ongoing work regarding treatment indications, from orphan diseases to common disorders, continuous versus intermittent treatment, the pharmacokinetics, pharmacodynamics, and optimal dosages of the different drugs, as well as the need for Phase IV trials, exhaustive registries, and long-term follow-up of several patient cohorts.Keywords: inflammation, interleukin-1, cytokines, treatment Pierre QuartierDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2011, Iss default, Pp 9-18 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Pierre Quartier Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
description	Pierre QuartierUnit&eacute; d&#39;Immunologie-H&eacute;matologie et Rhumatologie p&eacute;diatriques, H&ocirc;pital Necker-Enfants Malades, Assistance Publique-H&ocirc;pitaux de Paris, Paris, FranceAbstract: Cryopyrin-associated periodic syndrome (CAPS) include a group of rare autoinflammatory disorders, the spectrum of which ranges from the mildest form, ie, familial cold autoinflammatory syndrome to more severe phenotypes, ie, Muckle-Wells syndrome, and chronic infantile neurological cutaneous and articular syndrome, also known as neonatal-onset multisystem inflammatory disease. Three interleukin (IL)-1 antagonists have been tested in adults and children with CAPS, ie, anakinra, a recombinant homolog of the human IL-1 receptor antagonist; rilonacept, a fusion protein comprising the extracellular domains of IL-1 receptor I and the IL-1 adaptor protein, IL-1RAcP, attached to a human immunoglobulin G molecule; and canakinumab, the anti-IL-1&beta; monoclonal antibody. Following rapid clinical development, rilonacept and canakinumab were approved by both the US Food and Drug Administration and the European Medicines Agency for use in adults and children. This review describes how the study of CAPS has helped us to understand better the way the innate immune system works, the pathogenesis of autoinflammatory syndromes, and the key role of IL-1. It also reviews the effects of IL-1 blockade in CAPS and other disorders, in particular systemic juvenile idiopathic arthritis, adult-onset Still&#39;s disease, and gout. Finally, this review covers some issues addressed by very recent and ongoing work regarding treatment indications, from orphan diseases to common disorders, continuous versus intermittent treatment, the pharmacokinetics, pharmacodynamics, and optimal dosages of the different drugs, as well as the need for Phase IV trials, exhaustive registries, and long-term follow-up of several patient cohorts.Keywords: inflammation, interleukin-1, cytokines, treatment
format	article
author	Pierre Quartier
author_facet	Pierre Quartier
author_sort	Pierre Quartier
title	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
title_short	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
title_full	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
title_fullStr	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
title_full_unstemmed	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
title_sort	interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/446ea80268374ac1b79e916b181dfcf9
work_keys_str_mv	AT pierrequartier interleukin1antagonistsinthetreatmentofautoinflammatorysyndromesincludingcryopyrinassociatedperiodicsyndrome
_version_	1718396045484883968

Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome

Ejemplares similares